Glenmark enters into a collaboration with True North for its orthopaedic and pain management business in India

10 Aug 2018 | Read More

Glenmark’s consolidated revenue at Rs. 21,656.17 Mn. for Q1 FY 2018 – 19

10 Aug 2018 | Read More

Glenmark Pharmaceuticals Announces FDA Acceptance of the Company’s First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis

8 Aug 2018 | Read More

Glenmark Pharmaceuticals’ partner Elite Pharmaceuticals receives US FDA approval for generic methadone hydrochloride tablets

7 Aug 2018 | Read More

Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

6 Aug 2018 | Read More

Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab

26 Jul 2018 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet

17 Jul 2018 | Read More

Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of CINV (chemotherapy-induced nausea and vomiting)

10 Jul 2018 | Read More

Glenmark Announces Exclusive Licensing Agreement with Seqirus for its Investigational Seasonal Allergic Rhinitis Nasal Spray – Ryaltris – for Australia and New Zealand Markets

6 Jul 2018 | Read More

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

19 Jun 2018 | Read More

Glenmark Pharmaceuticals receives ANDA approval for HAILEY 1.5/30 and HAILEY Fe 1.5/30

6 Jun 2018 | Read More

Glenmark’s consolidated revenue at Rs. 22,798.16 Mn. for Q4 FY 2017 – 18

29 May 2018 | Read More

Glenmark Pharmaceuticals Announces Poster Presentations on GBR 1302 and GBR 1342, HER2xCD3 and CD38xCD3 Bispecific Antibodies, at the 2018 ASCO Annual Meeting

28 May 2018 | Read More

Glenmark Pharmaceuticals Announces the Company’s First New Drug Application Submission for RyaltrisTM for Patients with Seasonal Allergic Rhinitis

22 May 2018 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride Tablets, 625 mg

21 May 2018 | Read More

Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting

18 May 2018 | Read More

Glenmark announces grant of substitution and successful launch of generic Seretide® Accuhaler® in Denmark

16 May 2018 | Read More

New and Updated Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis, Including an Oral Presentation, to be Presented at the International Investigative Dermatology Meeting

10 May 2018 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Topical Solution USP, 0.05%

20 Apr 2018 | Read More

Glenmark receives ANDA approval for Tacrolimus Ointment, 0.1%

18 Apr 2018 | Read More

Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis

17 Apr 2018 | Read More

Glenmark Pharmaceuticals and Helsinn Group enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal

4 Apr 2018 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05%

27 Mar 2018 | Read More

Glenmark Pharmaceuticals Presents New Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress

6 Mar 2018 | Read More

Glenmark launches a globally-renowned hair growth formula Nourkrin® Woman in India

28 Feb 2018 | Read More

Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea, for Ophthalmic Solution Products

22 Feb 2018 | Read More

Glenmark Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting

19 Feb 2018 | Read More

Glenmark’s consolidated revenue at Rs. 22,036.62 Mn for Q3 FY 2017 – 18

9 Feb 2018 | Read More

Glenmark presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium

25 Jan 2018 | Read More

Glenmark initiates Phase IIb dose range finding study for novel molecule GRC 27864

15 Jan 2018 | Read More

Glenmark launches the biosimilar of Adalimumab in India

4 Jan 2018 | Read More